Sanofi SA (EPA:SAN) has been given a €82.00 ($95.35) price target by investment analysts at Goldman Sachs Group, Inc. (The) in a report issued on Wednesday. The firm presently has a “neutral” rating on the stock.

SAN has been the subject of a number of other reports. Jefferies Group LLC set a €92.00 ($106.98) price target on shares of Sanofi SA and gave the company a “neutral” rating in a report on Friday, May 12th. Morgan Stanley set a €91.00 ($105.81) price target on shares of Sanofi SA and gave the company a “buy” rating in a report on Tuesday, May 2nd. Sanford C. Bernstein set a €91.00 ($105.81) price target on shares of Sanofi SA and gave the company a “neutral” rating in a report on Tuesday, May 2nd. Kepler Capital Markets set a €92.00 ($106.98) price target on shares of Sanofi SA and gave the company a “buy” rating in a report on Wednesday, April 12th. Finally, J P Morgan Chase & Co reissued a “neutral” rating on shares of Sanofi SA in a report on Thursday, July 20th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of €88.19 ($102.54).

Sanofi SA (SAN) opened at 82.74 on Wednesday. The firm has a market cap of €104.48 billion and a PE ratio of 11.45. The firm’s 50-day moving average is €25.48 and its 200-day moving average is €25.74. Sanofi SA has a 12 month low of €62.50 and a 12 month high of €92.97.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another publication, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/07/26/sanofi-sa-epasan-given-a-82-00-price-target-at-goldman-sachs-group-inc-the.html.

About Sanofi SA

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Analyst Recommendations for Sanofi SA (EPA:SAN)

Receive News & Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related companies with MarketBeat.com's FREE daily email newsletter.